Ausgewählte Studien

Kaaz K, Szepietowski JC, Matusiak Ł. Kaaz K, et al. Acta Derm Venereol. 2019 Feb 1;99(2):175-180. doi: 10.2340/00015555-3065. Acta Derm Venereol. …Den ganzen Artikel lesen

Z Rheumatol. 2023 Mar 1. doi: 10.1007/s00393-023-01326-5. Online ahead of print. ABSTRACT Psoriatic arthritis (PsA) is a systemic immune-mediated inflammatory disease of the musculoskeletal system, which is accompanied by a chronic and progressive course. It is characterized by different clinical manifestations and can severely impair the quality of life and function of patients due to the existing heterogeneity of the manifestations. The (early) diagnosis of PsA and individualized therapeutic m

Life (Basel). 2023 Feb 2;13(2):419. doi: 10.3390/life13020419. ABSTRACT Interleukin 17 (IL-17) is an effector cytokine that plays a key role in the pathogenesis of both psoriasis and metabolic-associated fatty liver disease (MAFLD), a condition that is more prevalent and severe in patients with psoriasis. In liver inflammation, IL-17 is mainly produced by CD4+ T (TH17) and CD8+ T cells (Tc17), although numerous other cells (macrophages, natural killer cells, neutrophils and Tγδ cells) also contr

Pre-clinical and clinical evidence for suppression of alcohol intake by apremilast 1Department of Behavioral Neuroscience, Oregon Health & Science …Den ganzen Artikel lesen

Full text linksCite Display options Display options Background: Psoriasis (Ps) is a multisystem inflammatory disease associated with several …Den ganzen Artikel lesen

LETTER TO THE EDITOR Identification of children at risk for the development of severe paediatric plaque psoriasis: findings from the prospective …Den ganzen Artikel lesen

LETTER TO THE EDITOR Taufiq Salahuddin Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA Annika Hebbe Rocky Mountain …Den ganzen Artikel lesen

Biologic therapies for psoriasis can cause paradoxical eczema. The role of genetic factors in its pathogenesis are unknown. To identify risk …Den ganzen Artikel lesen

Actas Dermosifiliogr. 2023 Feb 14:S0001-7310(23)00144-8. doi: 10.1016/j.ad.2023.02.002. Online ahead of print. ABSTRACT Defining quality indicators is a key strategy for ensuring the quality and standardization of health care. The CUDERMA project, an initiative of the Spanish Academy of Dermatology and Venerology (AEDV), was undertaken to define quality indicators for the certification of specialized units in dermatology; the first 2 areas selected were psoriasis and dermato-oncology. The aim of

Ann Rheum Dis. 2023 Feb 14:ard-2022-223499. doi: 10.1136/ard-2022-223499. Online ahead of print. ABSTRACT OBJECTIVES: To investigate factors associated with severe COVID-19 in people with psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). METHODS: Demographic data, clinical characteristics and COVID-19 outcome severity of adults with PsO, PsA and axSpA were obtained from two international physician-reported registries. A three-point ordinal COVID-19 severity scale wa

Front Public Health. 2023 Jan 26;11:1000776. doi: 10.3389/fpubh.2023.1000776. eCollection 2023. ABSTRACT INTRODUCTION: Psoriasis is a chronic disease involving the skin, which significantly impacts the quality of life. Disease severity and treatment efficacy (i.e., response) are assessed through the Psoriasis Area and Severity Index (PASI). A PASI 75 response, i.e., an improvement of at least 75% with respect to the baseline PASI score, has traditionally been used as a therapeutic benchmark in c

Ther Adv Musculoskelet Dis. 2023 Feb 7;15:1759720X221149965. doi: 10.1177/1759720X221149965. eCollection 2023. ABSTRACT BACKGROUND: Tofacitinib is a Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA) and has been investigated for psoriasis (PsO). OBJECTIVES: This post hoc analysis examined baseline cardiovascular (CV) disease risk and its association with the occurrence of major adverse cardiovascular events (MACE) and malignancies in tofacitinib-treated patients with PsA and

Den ganzen Artikel lesen

Rapid Communication|Articles in Press Academic & Personal: 24 hour online access • Corporate R&D Professionals: 24 hour online access Powered …Den ganzen Artikel lesen

SummaryPsoriasis is a common chronic inflammatory skin disease that causes systemic inflammation and severely impacts the patient's quality of life. …Den ganzen Artikel lesen

Br J Dermatol. 2023 Feb 10:ljad030. doi: 10.1093/bjd/ljad030. Online ahead of print. NO ABSTRACT PMID:36763046 | DOI:10.1093/bjd/ljad030 Den ganzen Artikel lesen

Full text linksCite Display options Display options Background: Itch is the most bothersome symptom reported by patients with psoriasis. Safe and …Den ganzen Artikel lesen

Full text linksCite Display options Display options Curcumin (CUR) is a polyphenol extracted from the rhizome of Curcuma longa that possesses potent …Den ganzen Artikel lesen

Dear Editor, Biologic agents selectively targeting interleukin (IL)23 represent a breakthrough in the treatment of patients with moderate–severe …Den ganzen Artikel lesen

Background: Evidence suggests an association between atopic eczema (AE) or psoriasis and mental illness; however, the factors associated with mental …Den ganzen Artikel lesen

Introduction: The management of moderate-to-severe forms of psoriasis is becoming a frequent concern in geriatric age due to the higher risk to …Den ganzen Artikel lesen

Megna M, Camela E, Battista T, Genco L, Martora F, Noto M, Picone V, Ruggiero A, Monfrecola G, Fabbrocini G, Potestio L. Megna M, et al. Expert Opin …Den ganzen Artikel lesen

EudraCT Number: 2021-004131-84 Sponsor Protocol Number: ChronIA001 Start Date*: 2022-02-14 Sponsor Name:Erasmus Medical Center Full Title: Chronotherapy …Den ganzen Artikel lesen

Lancet. 2023 Feb 3:S0140-6736(23)00022-3. doi: 10.1016/S0140-6736(23)00022-3. Online ahead of print. ABSTRACT BACKGROUND: Few therapeutic options are available for patients with moderate-to-severe hidradenitis suppurativa. We aimed to assess the efficacy of secukinumab in patients with moderate-to-severe hidradenitis suppurativa in two randomised trials. METHODS: SUNSHINE and SUNRISE were identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials done in 219 primary site

Den ganzen Artikel lesen